PHVS
PharvarisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PHVS Profile
Pharvaris N.V.
A clinical-stage company that develops novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks
Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands
--
Pharvaris N.V. was incorporated in the Netherlands on September 30, 2015. They are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for unmet needs for rare diseases, with an initial focus on angioedema and other bradykinin-mediated diseases. Their first molecule, PHA 121, is a novel small molecule bradykinin B2 receptor antagonist for the treatment of hereditary angioedema, or HAE.
